

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): ~~[[Use]] A pharmaceutical composition for treating a cutaneous vascularization disorder, comprising a cutaneous vascularization disorder treating effective amount of metronidazole for the preparation of a pharmaceutical composition for treating a cutaneous vascularization disorder.~~

Claim 2 (Currently Amended): ~~[[Use]] The composition according to Claim 1, characterized in that the wherein said cutaneous vascular disorder involves at least one receptor chosen selected from the group comprising consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.~~

Claim 3 (Currently Amended): ~~[[Use]] The composition according to Claim 1 [[or 2]], characterized in that the wherein said cutaneous vascular disorder involves at least two receptors chosen selected from the group comprising consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.~~

Claim 4 (Currently Amended): ~~[[Use]] The composition according to any one of Claims 1 to 3, characterized in that the Claim 1, wherein said cutaneous vascular disorder involves at least three receptors chosen selected from the group comprising consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.~~

Claim 5 (Currently Amended): ~~[[Use]] The composition according to any one of Claims 1 to 4, characterized in that the Claim 1, wherein said cutaneous vascular disorder~~

involves at least four receptors ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

Claim 6 (Currently Amended): ~~Use of metronidazole~~ The composition according to ~~any one of Claims 1 to 5, characterized in that the~~ Claim 1, wherein said cutaneous vascular disorder involves at least five receptors ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

Claim 7 (Currently Amended): ~~[[Use]]~~ The composition according to Claim 1, ~~characterized in that the~~ wherein said vascular disorder is a component of rosacea and ~~in that~~ metronidazole is capable of interacting with at least one receptor ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

Claim 8 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 7, characterized in that~~ Claim 1, wherein metronidazole inhibits the binding of at least one natural ligand to its receptor, the ~~[[said]]~~ receptor being ~~chosen~~ selected from the group ~~comprising~~ consisting of the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.

Claim 9 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 8, characterized in that the~~ Claim 1, wherein said pharmaceutical composition is a dermatological composition for topical application.

Claim 10 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of~~
~~Claims 1 to 9, characterized in that~~ Claim 1, wherein the composition is for treating at least
one stage of rosacea.

Claim 11 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of~~
~~Claims 1 to 10, characterized in that~~ Claim 1, wherein the composition is for treating the first
stage of rosacea.

Claim 12 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of~~
~~Claims 1 to 11, characterized in that~~ Claim 1, wherein the composition is for treating the
second stage of rosacea.

Claim 13 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of~~
~~Claims 1 to 12, characterized in that~~ Claim 1, wherein the composition is for treating the third
stage of rosacea.

Claim 14 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of~~
~~Claims 1 to 13, characterized in that~~ Claim 1, wherein the composition is for treating the
fourth stage of rosacea.

Claim 15 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of~~
~~Claims 1 to 14, characterized in that the~~ Claim 1, wherein said composition contains from
0.0001% to 20% by weight, ~~preferably from 0.1% to 2%, and more preferentially from about~~
~~0.75% to 1% by weight~~ of metronidazole.

Claim 16 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 15, characterized in that the said composition also contains Claim 1, further~~ comprising another active agent ~~chosen~~ selected from the group consisting of antibiotics, antibacterial agents, antiviral agents, anti-parasitic agents, antifungal agents, anaesthetics, analgesics, anti-allergic agents, retinoids, free-radical scavengers, anti-pruriginous agents, keratolytic agents, anti-seborrhoeic agents, antihistamines, sulfides, immunosuppressant products and anti-proliferative products.

Claim 17 (Currently Amended): ~~[[Use]]~~ The composition according to ~~any one of Claims 1 to 16, characterized in that the composition contains Claim 1, further comprising an~~ additive ~~chosen~~ selected from the group consisting of sequestrants, antioxidants, sunscreens, preserving agents, fillers, electrolytes, humectants, colorants common mineral or organic acids or bases, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, skin calmativ and protective agents, pro-penetrating agents and gelling agents, or a mixture thereof.

Claim 18 (New): The composition according to Claim 15, wherein said composition contains from 0.1% to 2% by weight of metronidazole.

Claim 19 (New): The composition according to Claim 18, wherein said composition contains from about 0.75% to 1% by weight of metronidazole.